2 results
Approved WMOPending
Primary Objectives:* To compare overall survival (OS) of patients who receive NKTR-102given once every 21 days (q21d) to patients who receive Treatment ofPhysician*s Choice (TPC) selected from the following list of seven singleagentintravenous…
Approved WMORecruiting
To assess the feasibility and safety of intraoperative dual-modality imaging in patients with renal cell carcinoma with Indium-111-DOTA-girentuximab-IRDye800CW. Secondary objectives are to assess how intraoperative fluorescence imaging results…